Novartis Announces Agreement With Alnylam for Liver Therapy
(Bloomberg) -- Agreement to bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers, according to e-mailed statement.
Companies agree to collaborate on discovery & development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver disease
Collaboration aims to develop liver-targeted therapy as a potential alternative to transplantation for patients experiencing liver failure
This comes on top of the Lygenesis new I posted
Not only am I totally convinced major advances are coming to help. I think
there is an opportunity to make some ourselves some money too!!